---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-004778"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2022-03-28T23:59:59+00:00"
generated_at: "2026-06-26T16:34:53.911603+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Bioworks FY2021 revenue $314M (+309% YoY); 2022 guidance $325-340M

## Summary
- Full-year 2021 total revenue $314M, up 309% YoY; Foundry revenue $113M (+91%), Biosecurity $201M (exceeded $110M outlook).
- Added 31 new Cell Programs in 2021 (+72% YoY); 2022 guidance expects 60 new programs.
- Q4 2021 total revenue $148M vs $32M YoY; Adjusted EBITDA $1M vs $(51)M in prior year.
- GAAP loss from ops $(1.8)B including $1.7B catch-up stock comp; cash balance >$1.5B.
- Announced two tuck-in acquisitions in 2022: Project Beacon (COVID testing) and FGen (strain optimization).

## SEC filing metadata
- accession: 0000950170-22-004778
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2022-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000095017022004778/0000950170-22-004778-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000095017022004778/dna-20220328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-004778
- JSON: https://secwatch.observer/filing/0000950170-22-004778.json
- Plain text: https://secwatch.observer/filing/0000950170-22-004778.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.